Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON40961
NL-OMON40961
Completed
Not Applicable

Characterisation of neurotransmitter network dysfunction in MRI-negative localisation-related epilepsy - Neurotransmitter network dysfunction in epilepsy

Medisch Universitair Ziekenhuis Maastricht0 sites24 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEpilepsyfalling sickness10039911

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Epilepsy
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
24
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
November 15, 2016
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • •Subjects must be older than 18 years and able to give informed consent. ;Epilepsy patients:
  • •\- Diagnosed with cryptogenic localization\-related epilepsy with an epileptic focus in the frontal or temporal lobe (using EEG)
  • •\- Seizure frequency below 13/year.
  • •\- No changes in anti\-epileptic drugs (medication or dose) in the last 6 months.

Exclusion Criteria

  • •\- MRI visible lesions, as seen on the clinical 3T scans
  • •\- All absolute or relative contraindications for MR scanning.
  • •\- A medical history with cerebral diseases (other than epilepsy), vascular problems, diabetes mellitus, hypertension and/or cerebral surgery.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Onderzoek naar afwijkingen in het brein netwerk bij epilepsieepilepsy
NL-OMON25197Academic hospital Maastricht (azM)20
Recruiting
Not Applicable
iNTD (International Network on Neurotransmitter related Disorders) Registry
DRKS00007878niversitätsklinikum Heidelberg500
Completed
Not Applicable
A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patientsFTLD-ALS spectrum
JPRN-UMIN000038620ational Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology50
Recruiting
Not Applicable
A study of the connectivity measures of a resting-state brain network in patients with Epilepsy.EpilepsyNeurological - Epilepsy
ACTRN12618000193279The Royal Melbourne Hospital60
Active, not recruiting
Not Applicable
Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffering from schizophrenia treated with quetiapine (Seroquel®). - Quetiapine-StudyPatients have to fulfill the diagnostic criteria of a schizophrenia according to DSM-IV.
EUCTR2006-002342-11-DEKlinikum Fulda gAG22